INTERVENTION 1:	Intervention	0
Abraxane, Carboplatin, Bevacizumab	Intervention	1
carboplatin	CHEBI:31355	10-21
Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15	Intervention	2
carboplatin	CHEBI:31355	48-59
Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..	Intervention	3
disease	DOID:4,OGMS:0000031	107-114
death	OAE:0000632	172-177
Bevacizumab: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.	Intervention	4
disease	DOID:4,OGMS:0000031	94-101
death	OAE:0000632	158-163
Carboplatin: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.	Intervention	5
carboplatin	CHEBI:31355	0-11
area	PATO:0001323	13-17
auc	BAO:0002120	31-34
disease	DOID:4,OGMS:0000031	125-132
death	OAE:0000632	190-195
Inclusion Criteria:	Eligibility	0
Tissue block containing tumor to confirm metastatic breast cancer is required;	Eligibility	1
tissue	UBERON:0000479	0-6
breast cancer	DOID:1612	52-65
Measurable disease according to RECIST criteria	Eligibility	2
disease	DOID:4,OGMS:0000031	11-18
"Triple negative" disease defined as tumor demonstrating no expression for estrogen, progesterone or human epidermal growth factor receptor 2(HER2)receptors. "No expression" is categorized as  10% of cells staining or Allred  2;	Eligibility	3
disease	DOID:4,OGMS:0000031	18-25
estrogen	CHEBI:50114,BAO:0000760	75-83
progesterone	CHEBI:17026	85-97
growth factor	BAO:0002024	117-130
receptor	BAO:0000281	131-139
receptor	BAO:0000281	147-155
Aged 18 years or older;	Eligibility	4
Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0 or 1; life expectancy  3 months;	Eligibility	5
group	CHEBI:24433	29-34
Patients may have received 0 - 1 prior therapies (except taxanes in the metastatic setting). An interval of at least 1 week must have elapsed since prior chemotherapy or hormonal therapy for metastatic disease; at least 6 months must have elapsed since prior adjuvant therapy;	Eligibility	6
week	UO:0000034	119-123
disease	DOID:4,OGMS:0000031	202-209
adjuvant	CHEBI:60809	259-267
2 weeks between surgery and study enrollment ( 4 weeks between major surgery (defined as open abdominal/thoracic/cardiac) and study enrollment;	Eligibility	7
surgery	OAE:0000067	16-23
surgery	OAE:0000067	69-76
Laboratory tests performed within 14 days of study entry:	Eligibility	8
Granulocytes  1,500/µL;	Eligibility	9
Platelets  100,000/µL;	Eligibility	10
Hemoglobin  9 gm/dL;	Eligibility	11
hemoglobin	CHEBI:35143	0-10
Total bilirubin  institutional upper limit of normal (ULN);	Eligibility	12
Aspartate transaminase (AST) and alanine aminotransferase (ALT)  5 times ULN;	Eligibility	13
aspartate	CHEBI:29995	0-9
alanine	CHEBI:16449	33-40
Alkaline phosphatase  2.5 times ULN;	Eligibility	14
phosphatase	GO:0016791,BAO:0000295	9-20
Estimated creatinine clearance  60 mL/min.	Eligibility	15
creatinine clearance	CMO:0000765	10-30
left ventricular ejection fraction (LVEF) 50% by multigated acquisition (MUGA)/Echocardiogram;	Eligibility	16
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
Informed consent to receive protocol treatment, to provide biologic specimens, and to complete neurotoxicity questionnaires;	Eligibility	17
Cognitive and communication skills to comply with study and/or follow-up procedures;	Eligibility	18
No reproductive potential:	Eligibility	19
If pre-menopausal: Negative serum pregnancy test and patient agreement to use adequate contraceptive method (abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during and for 3 months after completion of treatment.	Eligibility	20
patient	HADO:0000008,OAE:0001817	53-60
If post-menopausal: Amenorrhea for  12 months.	Eligibility	21
amenorrhea	HP:0000141,DOID:13938	20-30
Exclusion Criteria:	Eligibility	22
Pregnant or breast feeding;	Eligibility	23
breast	UBERON:0000310	12-18
Prior treatment with Abraxane®, carboplatin or bevacizumab, or any taxane for metastatic breast cancer;	Eligibility	24
carboplatin	CHEBI:31355	32-43
taxane	CHEBI:36064	67-73
breast cancer	DOID:1612	89-102
Known hypersensitivity to any component of any study drug;	Eligibility	25
hypersensitivity	GO:0002524,DOID:1205	6-22
drug	CHEBI:23888	53-57
Active infection;	Eligibility	26
active	PATO:0002354	0-6
Current neuropathy  grade 2;	Eligibility	27
neuropathy	DOID:870	8-18
central nervous system (CNS) metastases as determined by head CT with contrast;	Eligibility	28
central nervous system	UBERON:0001017	0-22
head	UBERON:0000033	57-61
ct	BAO:0002125	62-64
History of bleeding within the past 6 months or active bleeding disorder;	Eligibility	29
history	BFO:0000182	0-7
active	PATO:0002354	48-54
disorder	OGMS:0000045	64-72
Serious non-healing wound, ulcer or bone fracture;	Eligibility	30
ulcer	OAE:0004372	27-32
bone fracture	HP:0020110	36-49
Uncontrolled congestive heart failure (CHF), or history of myocardial infarction(MI), unstable angina, stroke, or transient ischemia within previous 6 months;	Eligibility	31
congestive heart failure	HP:0001635,DOID:6000	13-37
history	BFO:0000182	48-55
myocardial infarction	HP:0001658,DOID:5844	59-80
stroke	HP:0001297,DOID:6713	103-109
transient	HP:0025153	114-123
ischemia	DOID:326	124-132
Inadequately controlled hypertension (defined as systolic blood pressure < 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications; prior history of hypertensive crisis or hypertensive encephalopathy;	Eligibility	32
hypertension	HP:0000822,DOID:10763	24-36
systolic blood pressure	CMO:0000004	49-72
diastolic blood pressure	CMO:0000005	86-110
history	BFO:0000182	161-168
hypertensive crisis	HP:0100735	172-191
hypertensive encephalopathy	DOID:9427	195-222
Proteinuria (defined as urine protein: creatinine (UPC) ratio  1.0 or urine dipstick  2+.	Eligibility	33
proteinuria	HP:0000093,DOID:576	0-11
urine	UBERON:0001088	24-29
urine	UBERON:0001088	70-75
protein	CHEBI:36080,BAO:0000175	0-7
protein	CHEBI:36080,BAO:0000175	30-37
creatinine	CHEBI:16737	39-49
upc	CHEBI:165829	51-54
ratio	UO:0000190	56-61
Significant vascular disease (aortic aneurysm, aortic dissection) or symptomatic peripheral vascular disease;	Eligibility	34
vascular disease	DOID:178	12-28
vascular disease	DOID:178	92-108
aortic aneurysm	HP:0004942,DOID:3627	30-45
aortic dissection	HP:0002647,DOID:0080685	47-64
peripheral vascular disease	DOID:341	81-108
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within previous 6 months;	Eligibility	35
history	BFO:0000182	0-7
abscess	HP:0025615	79-86
Uncontrolled serious contraindicated medical condition or psychiatric illness.	Eligibility	36
condition	PDRO:0000129	45-54
Outcome Measurement:	Results	0
Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat Women With Stage IV or Inoperable Stage III "Triple Negative" Metastatic Breast Cancer.	Results	1
carboplatin	CHEBI:31355	120-131
breast cancer	DOID:1612	240-253
Best clinical response is based on RECIST criteria, the proportion in each response category along with the exact binomial confidence intervals are estimated. Toxicity summaries are also provided.	Results	2
Time frame: 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Abraxane, Carboplatin, Bevacizumab	Results	5
carboplatin	CHEBI:31355	27-38
Arm/Group Description: Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15	Results	6
carboplatin	CHEBI:31355	71-82
Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..	Results	7
disease	DOID:4,OGMS:0000031	107-114
death	OAE:0000632	172-177
Bevacizumab: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.	Results	8
disease	DOID:4,OGMS:0000031	94-101
death	OAE:0000632	158-163
Carboplatin: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.	Results	9
carboplatin	CHEBI:31355	0-11
area	PATO:0001323	13-17
auc	BAO:0002120	31-34
disease	DOID:4,OGMS:0000031	125-132
death	OAE:0000632	190-195
Overall Number of Participants Analyzed: 39	Results	10
Measure Type: Number	Results	11
Unit of Measure: percentage of participants  Complete Response: 18        (8 to 34)	Results	12
Partial Response: 69        (52 to 83)	Results	13
Stable Disease: 8        (2 to 21)	Results	14
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 5        (1 to 17)	Results	15
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Adverse Events 1:	Adverse Events	0
Total: 22/41 (53.66%)	Adverse Events	1
Anemia 1/41 (2.44%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
Dyspepsia 1/41 (2.44%)	Adverse Events	3
dyspepsia	HP:0410281	0-9
Mucositis oral 1/41 (2.44%)	Adverse Events	4
mucositis	DOID:0080178	0-9
Nausea 3/41 (7.32%)	Adverse Events	5
nausea	HP:0002018	0-6
Vomiting 1/41 (2.44%)	Adverse Events	6
vomiting	HP:0002013	0-8
Pain 3/41 (7.32%)	Adverse Events	7
pain	HP:0012531	0-4
Allergic reaction 1/41 (2.44%)	Adverse Events	8
Infections and infestations - Other, specify:  [1]1/41 (2.44%)	Adverse Events	9
Vascular access complication 3/41 (7.32%)	Adverse Events	10
Alanine aminotransferase increased 1/41 (2.44%)	Adverse Events	11
alanine	CHEBI:16449	0-7
